High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Huntington's disease (HD) is characterized by polyglutamine expansion in Huntingtin protein, leading to protein aggregation.
• Protein aggregation is a common feature in various neurodegenerative diseases, including Parkinson's, Alzheimer's, and prion diseases.
• The exact role of these aggregates in disease pathogenesis and cell death remains unclear.

Purpose of the Study:

• To develop a homogeneous assay for quantifying protein aggregates in a cellular model of Huntington's disease.
• To multiplex this assay with a protease release assay to measure cytotoxicity caused by protein aggregates.
• To screen a compound library to identify molecules that modulate protein aggregation and/or cytotoxicity.

Main Methods:

• Developed a homogeneous assay based on the detergent-insoluble property of Huntingtin protein aggregates.
• Multiplexed the protein aggregation assay with a protease release assay for simultaneous measurement of cytotoxicity.
• Screened a compound library using the multiplexed assay in a cellular model of Huntington's disease.

Main Results:

• The developed assay accurately quantifies protein aggregates in HD cellular models.
• The multiplexed assay successfully identified compounds that prevent cell death and/or modulate protein aggregation.
• Demonstrated the utility of the assay in identifying potential therapeutic compounds.

Conclusions:

• The developed multiplexed assay is effective for identifying compounds that target protein aggregation and cytotoxicity in HD.
• This screening approach is valuable for studying the pathogenesis of HD and other protein aggregation-related neurodegenerative diseases.
• The assay facilitates the development of high-throughput screening for novel therapeutics for neurodegenerative disorders.